3,4-dehydropiperidine derivatives having psychotropic activity

A 3,4-dehydropiperidine derivative of the formula (1) ##STR94## wherein R.sub.1 is a hydrogen atom or an alkyl group having 1-3 carbon atoms;

• wherein R.sub.2 represents a group of the formula ##STR95## wherein A is a branched or non-branched alkylene group having 2 to 10 carbon atoms,
• R.sub.5 is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, and
• R.sub.6 is an unsubstituted or substituted aryl or heteroaryl group, said heteroaryl group being selected from thienyl, furyl, pyridyl, quinolyl, pyrimidyl, imidazolyl, pyrrolyl, oxadiazolyl, pyrazinyl and indolyl, wherein the substituents are selected from the group consisting of halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, esterified or etherified hydroxy, trifluoromethyl, alkylcarbonyl, cyano, C.sub.1 -C.sub.4 alkylamino and di(C.sub.1 -C.sub.4)alkylamino;
• a saturated or unsaturated C.sub.1 -C.sub.10 aliphatic or C.sub.4 -C.sub.10 cycloaliphatic hydrocarbon group;
• an unsubstituted or substituted aralkyl group substituted with halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, trifluoromethyl, alkylcarbonyl, cyano, C.sub.1 -C.sub.4 alkylamino or di(C.sub.1 -C.sub.4) alkylamino;
• or a heterocyclic ring system selected from the group consisting of tetrahydrofuryl, tetrahydropyranyl, piperidyl and pyrrolidinyl which may be substituted with one or more substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl, oxo and halogen;
• n has the value 1 or 2;
• and
• Z is one of the groups of the formulas 15 or 16 with the proviso that group 15 may be bound to the piperidine group via position 4 or 7 and the group 17 may be bound to the piperidine group via the indicated position in which groups R.sub.3 and R.sub.3 ' may be equal or different and represent hydrogen atoms;
• halogen atoms;
• oxo functions;
• saturated or unsaturated C.sub.1 -C.sub.10 aliphatic hydrocarbon groups;
• C.sub.1 -C.sub.6 hydroxyalkyl groups;
• esterified or etherified C.sub.1 -C.sub.6 hydroxyalkyl groups, wherein the ester group is derived from benzoic acid, from benzoic acid substituted with one or more equal or different substituents selected from the group consisting of halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, esterified or etherified hydroxy, trifluoromethyl, alkylcarbonyl, cyano, C.sub.1 -C.sub.4 alkylamino and di(C.sub.1 -C.sub.4)alkylamino, or from a straight or branched C.sub.2 -C.sub.8 aliphatic carboxylic acid, and wherein the ether group is a straight or branched, saturated or unsaturated aliphatic C.sub.1 -C.sub.8 hydrocarbyloxy group, a C.sub.3 -C.sub.6 cycloalkoxy group or a (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.4 alkoxy group;
• C.sub.1 -C.sub.4 alkylcarbonyl groups;
• hydroxy groups;
• amino groups;
• C.sub.1 -C.sub.3 alkylamino groups;
• di(C.sub.1 -C.sub.3)alkylamino groups;
• substituted or non-substituted aryl groups or heteroaryl groups, said heteroaryl groups being selected from thienyl, furyl, pyridyl, quinolyl, pyrimidyl, imidazolyl, pyrrolyl, oxadiazolyl, pyrazinyl and indolyl, wherein the substituents are selected from the group consisting of halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, esterified or etherified hydroxy, trifluoromethyl, alkylcarbonyl, cyano, C.sub.1 -C.sub.4 alkylamino and di(C.sub.1 -C.sub.4)alkylamino;
• or aryl(C.sub.1 -C.sub.3)alkyl groups;
• and R.sub.4 is a hydrogen atom, a halogen atom, a cyano group, a hydroxy group, a trifluoromethyl group, an alkyl group, an alkoxy group, an alkylthio group, an alkanoylamino group, an alkanoyl group, an aminocarbonyl group, an N-alkylaminocarbonyl group, an N,N-dialkylaminocarbonyl group, an alkanoyloxy group or an alkoxycarbonyl group, wherein the alkyl groups have 1 to 10 carbon atoms;
• or a pharmaceutically acceptable salt thereof.